By developing candidate VHH intrabodies, using in vitro selection techniques and straightforward protein engineering, we were able to rapidly investigate different mechanisms to interfere with PLN function, to finally deliver a unique molecule capable of in vivo activity in a murine heart failure model. The gene discussed is PLN; the disease is heart failure.